Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that it has acquired three brands viz. Disperzyme® (Trypsin BP 96 mg, Bromelain 180 mg & Rutoside Trihydrate 200 mg), Disperzyme-CD® (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) and Phlogam® (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) from Aksigen Hospital Care ("Aksigen"), a Mumbai based research driven healthcare entity with more than two decades of experience in the healthcare field. All the brands are approved by the Drugs Controller General of India ("DCGI") for post-operative inflammation in patients undergoing minor surgery and dental procedures.
Disperzyme® and Phlogam® are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside ("TBR") to complete a clinical study in India and get DCGI approval. The brands were registered and launched in India by Aksigen in 2013.
Kirti Ganorkar, CEO-India business, Sun Pharma, said, "The addition of Disperzyme® and Phlogam® further strengthens our anti-inflammatory portfolio. This systemic enzyme therapy combination is being used to control edema and it speeds-up the healing process. In a comparative clinical trial in India, the brands provided significantly better control and resolution of post-operative pain and inflammation."
The overall market of proteolytic enzyme for healing, pain and edema in India is around Rs.500 crores (as per IQVIA data MAT Nov 2022).
Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 1043.60 as compared to the previous close of Rs. 1039.95. The total number of shares traded during the day was 47234 in over 2979 trades.
The stock hit an intraday high of Rs. 1050.10 and intraday low of 1034.15. The net turnover during the day was Rs. 49211309.00.